Printer Friendly

CORDIS' SLEUTH ANGIOPLASTY CATHETER GAINS MARKET APPROVAL

 CORDIS' SLEUTH ANGIOPLASTY CATHETER GAINS MARKET APPROVAL
 MIAMI, July 20 /PRNewswire/ -- Cordis Corporation (NASDAQ-NMS: CORD)


said today that the Food and Drug Administration has approved the U.S. market release of its Sleuth PTCA Balloon Catheter, an advanced angioplasty device for opening coronary arteries occluded by the buildup of fatty deposits, or plaque, associated with atherosclerosis.
 Robert C. Strauss, Cordis president, called the approval "an important step in addressing customer needs in the over-the-wire segment of the market, which accounts for some 55 percent of all angioplasty procedures. The first of a number of new dilatation catheters that Cordis plans to introduce in fiscal 1993, Sleuth devices represent an important technical and strategic advancement for us in angioplasty, a market promising faster growth and higher margins than the company's core business, diagnostic angiography."
 Featuring a unique MaxTrax shaft system and a lubricous inner coating, Sleuth catheters offer exceptional handling and maneuverability -- performance features that enable the devices, guided by interventional cardiologists, to track tortuous vessels and cross severely diseased, difficult-to-reach lesions. Like other Cordis dilatation catheters, Sleuth catheters also incorporate a proprietary balloon material, Duralyn, which makes it possible for cardiologists to precisely match the balloon's size with the size of the lesion being treated.
 Joining Helix PTCA catheters, which broadly introduced in October 1991, Sleuth catheters represents Cordis' second line of over-the-wire dilatation devices. The company also markets Orion PTCA catheters to compete in the fixed-wire segment of the market, which currently accounts for less than 10 percent of all angioplasty procedures. Over- the-wire catheters are advanced to the treatment site over a guidewire; fixed-wire catheters, which generally feature very low profiles, are essentially balloons fused directly to guidewires.
 Cordis has become increasingly competitive in all facets of coronary angioplasty during the past three years. Totaling some $665 million worldwide and increasing 15 percent plus per year, the coronary angioplasty market is twice the size of, and increasing almost twice as fast as, diagnostic coronary angiography -- a market in which Cordis has long been the world leader and that has long fueled its growth.
 Shipments of Sleuth catheters to customers will begin later this month, the company said.
 Miami-based Cordis Corporation manufactures and markets a variety of medical devices and systems for the angiographic and neuroscience markets. Shares of the company's stock are traded on the NASDAQ National Market under the symbol CORD.
 -0- 7/20/92
 /CONTACT: Chick McDowell, vice president of corporate relations and assistant secretary of Cordis Corporation, 305-824-2821/
 (CORD) CO: Cordis Corporation ST: Florida IN: MTC SU:


AW-JB -- FL002 -- 0576 07/20/92 09:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 20, 1992
Words:431
Previous Article:SOCIETY CORPORATION ANNOUNCES THE ACQUISITION OF FIRST FEDERAL SAVINGS AND LOAN ASSOCIATION OF FORT MYERS
Next Article:PACIFIC SCIENTIFIC REPORTS SECOND QUARTER AND SIX-MONTH RESULTS
Topics:


Related Articles
ADVANCED INTERVENTIONAL SYSTEMS ADDS NEW CATHETER TO CLINICAL TRIALS WITH EXCIMER LASER SYSTEM
CORDIS' ORION SOFT TIP ANGIOPLASTY CATHETER GAINS MARKET APPROVAL
TWO NEW CORDIS ANGIOPLASTY CATHETERS GAIN U.S. MARKET RELEASE
CORDIS' SLEEK CATHETER RECEIVES "APPROVABLE LETTER"
FOUR CORDIS ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE
ANOTHER CORDIS ANGIOPLASTY CATHETER APPROVED FOR US MARKET RELEASE
CORDIS PREDATOR LONG BALLOON CATHETERS APPROVED FOR U.S. MARKET RELEASE
CORDIS TRAKSTAR ANGIOPLASTY CATHETERS APPROVED FOR US MARKET RELEASE
CORDIS GAINS FDA APPROVAL FOR FOUR NEW ANGIOPLASTY CATHETERS
LOCALMED RECEIVES THIRD FDA APPROVAL FOR CORONARY DRUG DELIVERY CATHETERS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters